What Happened?
San Diego, CA-based CODA-Biotherapeutics Appointed Mike Narachi as President and Chief Executive Officer
About the Company
CODA Biotherapeutics` revolutionary chemogenetic platform aims to control the activity of cells to treat disease. With chemogenetics, the goal is to modify a target cell population using gene therapy to express a tunable `switch` protein. Cells modified with the `switch` can be activated or inactivated in a dose-dependent manner by a subsequently administered small molecule therapeutic, an effect that should only occur in the modified cells.
About the Person
Mike Narachi is President and Chief Executive Officer at CODA Biotherapeutics. Previously, Mike held various senior HR leadership roles in the industry.
Info Source
News
Short Profile